Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;64(7):1563-1571.
doi: 10.1007/s00125-021-05424-4. Epub 2021 Mar 13.

Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis

Kasper B Kristensen  1 , Daniel P Henriksen  2   3 , Jesper Hallas  2 , Anton Pottegård  2 , Lars C Lund  2
Affiliations

Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis

Kasper B Kristensen et al. Diabetologia. 2021 Jul.

Abstract

Aims/hypothesis: Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) may reduce nephrolithiasis risk by increasing urine flow. We aimed to investigate whether initiation of SGLT2I was associated with reduced nephrolithiasis risk.

Methods: We conducted an active-comparator new-user cohort study using the Danish health registries in the period 11 November 2012 to 31 December 2018. Individuals aged ≥40 years initiating SGLT2Is or glucagon-like peptide-1 receptor agonists (GLP1 RAs) were followed from treatment initiation until an inpatient or outpatient diagnosis of nephrolithiasis, death, emigration or end of study. New users of SGLT2Is were matched 1:1 on propensity scores to new users of GLP1 RAs. In supplementary analyses, risk of recurrent nephrolithiasis was assessed in individuals with a history of nephrolithiasis before treatment initiation.

Results: We identified 24,290 and 19,576 eligible users of SGLT2Is and GLP1 RAs, respectively. After matching, 12,325 patient pairs remained. The median age was 61 years and median follow-up was 2.0 years. The nephrolithiasis rate was 2.0 per 1000 person-years in SGLT2I initiators compared with 4.0 per 1000 person-years in GLP1 RA initiators, with a rate difference of -1.9 per 1000 person-years (95% CI -2.8, -1.0) and an HR of 0.51 (95% CI 0.37, 0.71). For recurrent nephrolithiasis (n = 731 patient pairs), the rate difference was -17 per 1000 person-years (95% CI -33, -1.5) and the HR was 0.68 (95% CI 0.48, 0.97).

Conclusions/interpretation: Initiation of treatment with SGLT2Is was associated with a clinically significant reduced risk of incident and recurrent nephrolithiasis.

Keywords: Cohort studies; Databases; Dipeptidyl peptidase 4 inhibitors; Glucagon–like peptide 1 receptor agonists; Nephrolithiasis; Observational studies; Sodium–glucose cotransporter 2 inhibitors; Type 2 diabetes.

PubMed Disclaimer

Comment in

References

    1. Davies MJ, D’Alessio DA, Fradkin J et al (2018) Management of Hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia 61:2461–2498. https://doi.org/10.1007/s00125-018-4729-5
    1. Patorno E, Pawar A, Franklin JM et al (2019) Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPRISE study. Circulation 139(25):2822–2830. https://doi.org/10.1161/CIRCULATIONAHA.118.039177 - DOI - PubMed
    1. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720 - DOI - PubMed
    1. van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH (2017) SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome. Clin J Am Soc Nephrol 12(4):700–710. https://doi.org/10.2215/CJN.06080616
    1. Curhan GC (2007) Epidemiology of stone disease. Urol Clin N Am 34(3):287–293. https://doi.org/10.1016/j.ucl.2007.04.003 - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources